Idelib
THERAPEUTIC AREA: Oncology / Hematology + Onco-Hematology
ACTIVE PRINCIPLE: Idelalisib
PRESENTATION: 100 mg and 150 mg
INDICATION:
- B-Cell Chronic Lymphocytic Leukemia
- Follicular Lymphoma (LF) that is refractory
COUNTRIES WHERE IT IS MARKETED:
